Reporting of loss to follow-up information in randomised controlled trials with time-to-event outcomes: A literature survey

BMC Medical Research Methodology

Volumn 11, Issue , 2011, Pages

  Vervölgyi, Elke ^a   Kromp, Mandy ^a   Skipka, Guido ^a   Bender, Ralf ^a,b   Kaiser, Thomas ^a  

^a INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Kaplan Meier plot; loss to follow up; randomised controlled trial; survival analysis

Indexed keywords

EID: 80053173842     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-11-130     Document Type: Article

References (23)

1. Nonparametric estimation from incomplete observations. Kaplan EL, Meier P, Journal of the American Statistical Association 1958 53 457 481 10.2307/2281868
2. The most-cited statistical papers. Ryan TP, Woodall WH, Journal of Applied Statistics 2005 32 461 474 10.1080/02664760500079373 (Pubitemid 41070669)
3. Survival probabilities (the Kaplan-Meier method). Bland JM, Altman DG, BMJ 1998 317 7172 1572 9836663 (Pubitemid 128719735)
4. Time to event (survival) data. Altman DG, Bland JM, BMJ 1998 317 7156 468 469 9703534
5. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Pocock SJ, Clayton TC, Altman DG, Lancet 2002 359 1686-1689
6. Practical Statistics for Medical Research. Altman DG, Chapman & Hall/CRC 1999
7. Review of survival analyses published in cancer journals. Altman DG, De Stavola BL, Love SB, Stepniewska KA, British Journal of Cancer 1995 72 511-518
8. Survival end point reporting in randomized cancer clinical trials: A review of major journals. Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A, Journal of Clinical Oncology 2008 26 3721-3726
9. A note on quantifying follow-up studies of failure time. Schemper M, & Smith TL, Controlled Clinical Trials 1996 17 343-346
10. Nutzenbewertung der Statine unter besonderer Berücksichtigung von Atorvastatin: Arbeitspapier. http://www.iqwig.de/download/Arbeitspapier- Nutzenbewertung-der-Statine-unter-besonderer-Beruecksichtigung-von-Atorvastatin- .pdf
11. Clopidogrel versus Acetylsalicylsäure in der Sekundärprophylaxe vaskulärer Erkrankungen: Abschlussbericht; Auftrag A04-01A. http://www.iqwig.de/download/A04-01A-Abschlussbericht-Clopidogrel-versus-ASS-in- der-Sekundaerprophylaxe.pdf
12. A review of reporting of participant recruitment and retention in RCTs in six major journals. Toerien M, Brookes ST, Metcalfe C, de Salis I, Tomlin Z, Peters TJ, Sterne J, Donovan JL, Trials 2009 10 52
13. Glossary. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. http://www.cochrane.org/resources/handbook/
14. Statistical Models Based on Counting Processes. Andersen PK, Borgan O, Gill RD, Keiding N, New York: Springer 2 1997
15. Competing Risks: A Practical Perspective. Pintilie M, Chichester, England: John Wiley & Sons, Ltd 1 2006
16. Users' guide to the medical literature. 2. How to use an article about therapy or prevention. A. Are the results of the study valid? Guyatt GH, Sackett DL, Cook DJ, Journal of the American Medical Association 1993 270 2598 2601 10.1001/jama.270.21.2598 8230645 (Pubitemid 23346700)
17. Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots. Royston P, Parmar MK, Altman DG, J Natl Cancer Inst 2008 100 92 97 10.1093/jnci/djm265 18182621 (Pubitemid 351480561)
18. Quantification of the completeness of follow-up. Clark TG, Altman DG, De Stavola BL, Lancet 2002 359 1309 1310 10.1016/S0140-6736(02)08272-7 11965278 (Pubitemid 34310638)
19. Intention-to-treat principle. Montori VM, Guyatt GH, Can Med Ass J 2001 165 1339 1341 (Pubitemid 33044065)
20. Problems in dealing with missing data and informative censoring in clinical trials. Shih WJ, Current Controlled Trials in Cardiovascular Medicine 2002 3 1 4 10.1186/1468-6708-3-4 11985778
21. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG, BMJ 2010 340 869 10.1136/bmj.c869 20332511
22. Endorsement of the CONSORT statement by high impact medical journals: survey of instructions for authors. Altman DG, BMJ 2005 330 7499 1056 1057 10.1136/bmj.330.7499.1056 15879389 (Pubitemid 40646557)
23. Lost to follow-up Information in Trials (LOST-IT): a protocol on the potential impact. Akl EA, Briel M, You JJ, Lamontagne F, Gangji A, Cukierman-Yaffe T, Alshurafa M, Sun X, Nerenberg KA, Johnston BC, et al. Trials 2009 10 40